Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy
- Registration Number
- NCT00498745
- Lead Sponsor
- Puma Biotechnology, Inc.
- Brief Summary
To evaluate the comparative bioavailability of 2 new tablet formulations of HKI-272 with a reference capsule and an oral solution in healthy subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method The data from this study along with in vitro data will be used to explore in vitro/in vivo correlation for HKI-272 to support formulation development.
- Secondary Outcome Measures
Name Time Method